A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
Completed · Phase 1
Conditions studied: Cystic Fibrosis
In brief
The purpose of this study is to evaluate the relative bioavailability of a VX-828 tablet formulation compared to a suspension and evaluate its safety and tolerability.
Key facts
- Study ID
- NCT06861413
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 68
- Starts
- 2025-04-01
- Expected to finish
- 2025-05-05
- Last updated by the study team
- 2025-06-04
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Celerion - Tempe — Tempe, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.